Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant is currently attempting one of the most ambitious pivots in its 45-year history. While the company has built its multi-billion-dollar empire on bone health, oncology, and [...]
The Bureau of Labor Statistics released the December 2025 Consumer Price Index (CPI) report on the morning of January 13, 2026, revealing a headline inflation rate of 2.7%. While the headline figure remained steady, the real story for Wall Street lay in the "core" data—which excludes the volatile
NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five years.
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom" understanding of life. Developed by Google DeepMind and its commercial arm, Isomorphic Labs—both subsidiaries of Alphabet (NASDAQ: GOOGL)—the model has effectively bridged the gap between computational [...]
On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the highly regulated medical industry. Announced during the opening of the J.P. Morgan Healthcare Conference, the platform represents a strategic pivot for Anthropic, moving beyond general-purpose AI [...]
Nvidia said on Monday that it will partner with Eli Lilly to fund a new artificial intelligence research lab, committing up to $1 billion over five years.
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion "co-innovation" partnership at the J.P. Morgan Healthcare Conference on January 12, 2026. This five-year strategic alliance aims to re-engineer the
As the dust settles on the first trading weeks of 2026, the U.S. economy finds itself in a precarious yet surprisingly durable equilibrium. Despite a political landscape fraught with the friction of an upcoming midterm election cycle and a looming leadership transition at the Federal Reserve, the American labor
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The headline of Day 1 was undoubtedly the announcement of a massive strategic partnership between Eli Lilly and Company (NYSE:
